Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN SODIUM versus CEPTAZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN SODIUM versus CEPTAZ.
CEFAZOLIN SODIUM vs CEPTAZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP1a, PBP1b, PBP2a, PBP2b, PBP2x, PBP3, and PBP4, thereby preventing cross-linking of peptidoglycan chains. This leads to cell lysis and death.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and causing cell lysis.
1-2 g IV/IM every 8 hours; maximum 12 g/day for severe infections.
1 to 2 g intravenously every 8 to 12 hours; maximum 6 g per day.
None Documented
None Documented
Approximately 1.8 hours (range 1.2-2.2 h) in normal renal function; prolonged in renal impairment (up to 30-40 h in ESRD)
Approximately 2 hours in patients with normal renal function; prolonged to 3-5 hours in mild-moderate renal impairment and >20 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); minimal biliary (1-2%); fecal (<1%)
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <10%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic